Replimune REPL
NASDAQ REPL
$15.03 -0.26 (-1.70%)
As of: Sep 4, 2026 · 2:31 PM EDT

Replimune (REPL) Non-Current Debt (2019 - 2026)

Replimune (REPL) posted Non-Current Debt of $83.3 million for Q1 2026, up 74.91% sequentially from $47.6 million in Q4 2025, and up 79.63% YoY from $46.4 million in Q1 2025.

Analysis

Replimune (REPL) Non-Current Debt (2019 - 2026) Analysis & Trends

Replimune has reported Non-Current Debt for 7 years, with the latest figure at $83.3 million in Q1 2026.

  • Quarterly Non-Current Debt rose 79.63% year-over-year to $83.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $83.3 million (up 79.63% YoY) and the FY2026 annual result came in at $83.3 million, up 79.63% from the prior year.
  • Non-Current Debt grew to $83.3 million in Q1 2026 per REPL's latest filing, from $47.6 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $83.3 million in Q1 2026 and troughed at $28.4 million in Q4 2022.
  • A 5-year average of $43.7 million and a median of $45.4 million in 2024 frame the typical range for Non-Current Debt.
  • The sharpest annual moves came in 2024 and 2026: Non-Current Debt increased 3.43% in 2024, then soared 79.63% in 2026.
  • Over 5 years, Non-Current Debt stood at $28.4 million in 2022, then surged by 56.51% to $44.4 million in 2023, then increased by 3.43% to $46.0 million in 2024, then grew by 3.63% to $47.6 million in 2025, then soared by 74.91% to $83.3 million in 2026.
  • According to Business Quant data, Non-Current Debt over the past three periods registered $83.3 million, $47.6 million, and $47.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Vertex Pharmaceuticals 138.78 Bn 130.92 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.50 Bn 77.51 Bn 3.93 Bn 1.99 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn -
4 Moderna 58.06 Bn 52.92 Bn 52.00 Mn 591.00 Mn
5 Revolution Medicines 44.04 Bn 44.04 Bn - -
6 BeOne Medicines 40.04 Bn 34.94 Bn 1.53 Bn 882.16 Mn
7 Alnylam Pharmaceuticals 35.45 Bn 32.14 Bn 992.69 Mn -
8 Royalty Pharma 28.41 Bn 27.57 Bn - 8.96 Bn
9 Insmed 27.42 Bn 26.26 Bn 358.27 Mn 546.77 Mn
10 Replimune 1.45 Bn 1.45 Bn - 84.11 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 84.11 Mn
Mar 31, 2026 83.31 Mn
Dec 31, 2025 47.63 Mn
Sep 30, 2025 47.21 Mn
Jun 30, 2025 46.79 Mn
Mar 31, 2025 46.38 Mn
Dec 31, 2024 45.96 Mn
Sep 30, 2024 45.57 Mn
Jun 30, 2024 45.19 Mn
Mar 31, 2024 44.81 Mn
Dec 31, 2023 44.43 Mn
Sep 30, 2023 29.16 Mn
Jun 30, 2023 28.91 Mn
Mar 31, 2023 28.65 Mn
Dec 31, 2022 28.39 Mn
Sep 30, 2020 9.83 Mn
Jun 30, 2020 9.76 Mn
Mar 31, 2020 9.80 Mn
Dec 31, 2019 9.74 Mn
Sep 30, 2019 9.66 Mn